Improvement of Tardive Dyskinesias with Olanzapine.
Journal
Case reports in psychiatry
ISSN: 2090-682X
Titre abrégé: Case Rep Psychiatry
Pays: United States
ID NLM: 101583308
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
07
2023
revised:
14
09
2023
accepted:
21
09
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements that generally occur after prolonged exposure to neuroleptic medications. In this article, we present the case of a 29-year-old man with schizophrenia who developed TD following treatment with haloperidol. Despite various attempts with benzodiazepines, amantadine, and anticholinergics, the dyskinesias persisted. However, after 2 years of treatment with olanzapine alone, a progressive improvement occurred, leading to the complete disappearance of the dyskinesias. We also provide a brief review of reported cases of antipsychotic-induced TD that has improved with olanzapine.
Identifiants
pubmed: 37908858
doi: 10.1155/2023/6688623
pmc: PMC10615574
doi:
Types de publication
Case Reports
Langues
eng
Pagination
6688623Informations de copyright
Copyright © 2023 S. Echater and B. Oneib.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Am J Psychiatry. 2004 Mar;161(3):414-25
pubmed: 14992963
J Psychopharmacol. 2010 Jul;24(7):1121-5
pubmed: 19395427
Br J Psychiatry. 1991 Apr;158:503-10
pubmed: 1675900
Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):627-630
pubmed: 33124596
J Psychopharmacol. 2019 Oct;33(10):1187-1198
pubmed: 31347436
Neurology. 2001 Mar 27;56(6):805-7
pubmed: 11274325
J Clin Psychiatry. 1998 Jul;59(7):380-1
pubmed: 9714267
Am J Psychiatry. 2000 Feb;157(2):287-9
pubmed: 10671405
Br J Psychiatry. 1998 Feb;172:186
pubmed: 9519075
J Clin Psychopharmacol. 2008 Feb;28(1):69-73
pubmed: 18204344
Int Clin Psychopharmacol. 2005 Mar;20(2):79-85
pubmed: 15729082
Eur Psychiatry. 2001 Jun;16(4):259-60
pubmed: 11418277
Int J Neuropsychopharmacol. 1999 Dec;2(4):333-334
pubmed: 11285150
Indian J Psychol Med. 2013 Oct;35(4):423-4
pubmed: 24379512
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Sep;28(6):985-96
pubmed: 15380859
Ann Clin Psychiatry. 2008 Jul-Sep;20(3):139-44
pubmed: 18633740
J Clin Psychiatry. 2003 Nov;64(11):1342-8
pubmed: 14658949
J Clin Psychiatry. 2004 May;65(5):696-701
pubmed: 15163258
Int Clin Psychopharmacol. 2003 Nov;18(6):357-9
pubmed: 14571157
Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):815-7
pubmed: 12188112
Eur Psychiatry. 2000 Nov;15(7):438-9
pubmed: 11112937
Mov Disord. 2006 May;21(5):589-98
pubmed: 16532448
Encephale. 2016 Jun;42(3):248-54
pubmed: 26922134
J Clin Psychiatry. 2001 Apr;62(4):298-9
pubmed: 11379849
Case Rep Psychiatry. 2017;2017:7359095
pubmed: 28835863
Eur Psychiatry. 2000 Aug;15(5):338-9
pubmed: 10954879
Indian J Psychiatry. 2004 Oct;46(4):319-23
pubmed: 21206790
Prog Neuropsychopharmacol Biol Psychiatry. 2005 May;29(4):633-5
pubmed: 15866369
Curr Opin Psychiatry. 2008 Mar;21(2):151-6
pubmed: 18332662
Eur Psychiatry. 2002 Nov;17(7):421-4
pubmed: 12547311
Int J Clin Pract. 2003 Mar;57(2):147-9
pubmed: 12661802
Can J Psychiatry. 2005 Oct;50(11):703-14
pubmed: 16363464
J Clin Psychiatry. 1994 Sep;55 Suppl B:102-6
pubmed: 7961550